Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Targeting Apoptosis to Overcome Chemotherapy Resistance

In: Metastasis [Internet]. Brisbane (AU): Exon Publications; 2022 May 3. Chapter 12.
Affiliations
Free Books & Documents
Review

Targeting Apoptosis to Overcome Chemotherapy Resistance

Eda Dogan et al.
Free Books & Documents

Excerpt

Chemotherapy resistance is a major limiting factor for the extensive use of chemotherapeutic drugs in cancer treatment. Despite the large number of newly discovered medications, treatment success rates are still unsatisfactory. Programmed cell death, called apoptosis, is one of the main tissue homeostasis mechanisms that balances cell survival and death. Apoptosis can be induced through extrinsic and intrinsic pathways or repressed by inhibitor proteins. During tumor progression, homeostasis between the anti-apoptotic and pro-apoptotic regulators is disturbed and shifted towards survival through various escape mechanisms. Dysregulation of apoptosis-regulatory mediators, particularly high levels of anti-apoptotic proteins, is one of the main mechanisms by which tumor cells acquire resistance to chemo- and radiotherapy. Therefore, it is important to restore apoptosis in the chemo- and radiotherapy-resistant tumor cells. In this chapter, we summarize general chemotherapy resistance mechanisms, discuss the role of extrinsic and intrinsic pathways in chemoresistance, and review the current experimental strategies to overcome chemotherapy resistance targeting the apoptotic pathways.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare no potential conflict of interest with respect to research, authorship, and/or publication of this chapter.

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660 . - DOI - PubMed
    1. Al-Dimassi S, Abou-Antoun T, El-Sibai M. Cancer cell resistance mechanisms: A mini review. Clin Transl Oncol. 2014;16(6):511–6. https://doi.org/10.1007/s12094-014-1162-1 . - DOI - PubMed
    1. Abbas Z, Rehman S. An Overview of Cancer Treatment Modalities. Neoplasm. 2018 https://doi.org/10.5772/intechopen.76558 . - DOI
    1. Thirumaran R, Prendergast GC, Gilman PB. Cancer Immunotherapy. Elsevier Inc.; 2007. Cytotoxic Chemotherapy in Clinical Treatment of Cancer; pp. 101–116. https://doi.org/10.1016/B978-012372551-6/50071-7 . - DOI
    1. Kibria G, Hatakeyama H, Harashima H. Cancer multidrug resistance: Mechanisms involved and strategies for circumvention using a drug delivery system. Arch Pharm Res. 2014;37(1):4–15. https://doi.org/10.1007/s12272-013-0276-2 . - DOI - PubMed

LinkOut - more resources